{
  "id": 6672296,
  "title": "Pan-neutralization of parainfluenza viruses by a hemagglutinin-neuraminidase antibody",
  "url": "https://urgent.news/2026/09/10/pan-neutralization-of-parainfluenza-viruses-by-a-hemagglutinin",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-10T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.07.749649v1?rss=1"
  },
  "original_language": "en",
  "account": "Human parainfluenza viruses (HPIVs) can lead to serious respiratory issues like croup, bronchiolitis, and pneumonia, especially in children, the elderly, and those with weakened immune systems. Currently, there are no human vaccines or targeted treatments for these viruses. In this study, researchers unveiled a human monoclonal antibody called PVA269 that effectively neutralizes all four HPIV subtypes, PIV5, and Sendai virus. The antibody achieves this by engaging with the hemagglutinin-neuraminidase (HN) glycoprotein found on the virus. Through this interaction, PVA269 blocks the virus's ability to cause infection by inhibiting its neuraminidase activity and hemagglutination of red blood cells.\n\nThe researchers discovered that PVA269 cleverly adjusts its molecular structure to fit the unique characteristics of each HPIV subtype, such as the N-linked glycans present in the HPIV2 virus. This adaptability allows the antibody to be effective against a wide range of HPIV infections, spanning two viral genera. The findings reveal that PVA269 offers strong preventive effects against HPIV3 replication in both upper and lower respiratory tracts of cotton rats, a model commonly used to predict human outcomes. These results establish PVA269 as an exceptional monoclonal antibody and suggest it could be a valuable clinical candidate for preventing HPIV infections, transmission, and disease, particularly in vulnerable populations.",
  "summary": "Human parainfluenza viruses (HPIVs) can cause severe respiratory illnesses, such as croup, bronchiolitis, and pneumonia, particularly in children, the elderly and immunocompromised individuals. No vaccines or specific therapeutics are available for use in humans. Here, we report the discovery of a human monoclonal antibody designated PVA269 that broadly and potently neutralizes all four HPIV…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}